Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
Fierce Pharma
SEPTEMBER 20, 2024
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. With the nod, Dupixent becomes the first biologic treatment for COPD patients in the U.S.
Let's personalize your content